<?xml version="1.0" encoding="UTF-8"?>
<p>The antibodies in the CP could potentially limit the viral replication, can mediate cellular toxicity and/or phagocytosis, and the plasma components can exert vital clinical effects such as replacing the coagulation factors, complement activation. Also, CP may potentially offer the only short-term strategy to confer immediate immunity to infection susceptible patients [
 <xref rid="R53" ref-type="bibr">53</xref>]. In the absence of an effective specific treatment for COVID-19, clinicians across the globe have used the CP with varying success [
 <xref rid="R54" ref-type="bibr">54</xref>, 
 <xref rid="R55" ref-type="bibr">55</xref>].
</p>
